Femasys Inc（FEMY）资讯与事件FEMYFemasys Inc

Femasys Partners with SandsRx Pharmacy

Femasys announced an agreement with SandsRx Pharmacy, marking the first in a planned network of specialty pharmacy partnerships supporting the launch of FemaSeed and Femasys' comprehensive fertility portfolio to OB/GYN practices. The partnership complements a portfolio spanning diagnostics for women and men, sperm preparation and in-office fertility treatment by providing specialized pharmacy support, coordinated medication access and preferred pricing. For patients undergoing FemaSeed treatment, fertility medications may be prescribed to support ovulation and improve the likelihood of pregnancy.

Femasys Doubles FemBloc FINALE Trial Enrollment Sites to 12

Femasys announced that it has doubled the number of actively enrolling sites in its FemBloc FINALE Pivotal Trial to twelve across the United States. The coast-to-coast network of academic centers and private clinical practices now includes Baylor Research Institute and Columbia University Medical Center, joining existing academic sites Maimonides Medical Center, Stanford University, University of California Davis and the University of Utah. Participation by these prominent centers reflects broad clinical interest in advancing permanent birth control options for women through this landmark study and marks continued progress in Femasys' U.S. clinical program.

Femasys Partners with Minnesota Women's Care to Implement FemVue and FemaSeed Complete

Femasys announced that Minnesota Women's Care will implement FemVue for fertility diagnostic evaluation and FemaSeed Complete for in-office first-line fertility treatment across its four OB/GYN practice locations.